AG Mednet to Address Global Endpoint Adjudication Challenges

AG Mednet is presenting at the 4th Annual Endpoint Adjudication Conference taking place from May 1 to 2. The session titled “Overcome Global Endpoint Adjudication Challenges,” co-presented by Abraham Gutman, founder and president of AG Mednet, and Alisa Hummings, Global Head of the Clinical Event Validation for IQVIA, will address the complicated nature of adjudication […]

Read More...

Improve data management to improve endpoint adjudication success in clinical trials

In the winter issue of International Clinical Trials, CEO Abraham Gutman writes about how poor management of data is one of the factors ailing adverse event and endpoint adjudication in clinical trials. The clinical trial industry is transforming, and the vision for this is simple: embrace quality and automation across the clinical trial spectrum and […]

Read More...

Learn About AG Mednet’s Endpoint Adjudication Technology at Leading Clinical Trial Events This Fall

BOSTON – October 27, 2017 – As part of its mission to move the clinical trial industry even closer to the goal of zero-delay clinical trials, AG Mednet will both attend and exhibit at several key industry events this fall. A leader in clinical trial technology innovation, AG Mednet is reimagining how endpoint adjudication can […]

Read More...

AG Mednet Launches Endpoint Adjudication Technology to Ensure Data Quality

Judi helps sponsors and CROs manage clinical events from trigger to final adjudication   Boston, MA – May 2, 2017 – AG Mednet continues its drive to advance clinical trials with the launch of Judi, the first comprehensive electronic endpoint adjudication system to manage workflow and ensure data quality. Judi helps sponsors and CROs manage […]

Read More...

The power of notifications in trials with image-based eligibility criteria

  We are seeing more and more imaging trial protocols requiring the analysis of subject eligibility to occur under tightening deadlines. Take for example a cardiovascular study using centralized analysis of an Intra-Vascular Ultrasound (IVUS) to determine whether a subject should be included in the trial. In this particular protocol, the patient remains in the […]

Read More...